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Idiopathic pneumonia syndrome (IPS) is an acute, noninfectious lung disorder associated with high morbidity
and mortality after hematopoietic cell transplantation. Previous studies have suggested a role for TNFa in the
pathogenesis of IPS. We report a multicenter phase II trial investigating a soluble TNF-binding protein, eta-
nercept (Enbrel, Amgen, Thousand Oaks, CA), for the treatment of pediatric patients with IPS. Eligible patients
were < 18 years old, within 120 days after transplantation, and with radiographic evidence of a diffuse
pneumonitis. All patients underwent a pretherapy broncho-alveolor lavage (BAL) to establish the diagnosis of
IPS. Systemic corticosteroids (2.0 mg/kg/day) plus etanercept (.4 mg/kg twice weekly  8 doses) were
administered. Response was deﬁned as survival and discontinuation of supplemental oxygen support by day 28
of study. Thirty-nine patients (median age, 11 years; range, 1 to 17) were enrolled, with 11 of 39 patients
nonevaluable because of identiﬁcation of pathogens from their pretherapy BAL. In the remaining 28 patients,
the median fraction of inspired oxygen at study entry was 45%, with 17 of 28 requiring mechanical ventilation.
Complete responses were seen in 20 (71%) patients, with a median time to response of 10 days (range, 1 to 24).
Response rates were higher for patients not requiring mechanical ventilation at study entry (100% versus 53%,
P ¼ .01). Overall survival at 28 days and 1 year after therapy were 89% (95% conﬁdence interval [CI], 70% to 96%)
and 63% (95% CI, 42% to 79%), respectively. Plasma levels of proinﬂammatory cytokines were signiﬁcantly
increased at onset of therapy, subsequently decreasing in responding patients. The addition of etanercept to
high-dose corticosteroids was associated with high response rates and survival in children with IPS.
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Idiopathic pneumonia syndrome (IPS) describes an acute,
noninfectious lung injury after hematopoietic cell trans-
plantation (HCT). IPS responds poorly to conventional therapy,
with mortality rates of 50% to 80% within 28 days of diagnosis
Table 1
IPS Diagnostic Criteria
1. Presence of widespread alveolar injury:
a. Diffuse radiographic inﬁltrates on CXR or CT
b. SpO2  93% on room air, or supplemental oxygen required to
achieve SpO2 > 93%.
c. Clinical signs and symptoms (cough, rales, dyspnea)
2. Absence of lower respiratory tract infection, based upon BAL studies:
a. Gram stain, fungal stain, acid fast bacilli stain.
b. Bacterial*, fungal, viral (RSV, parainﬂuenza, adenovirus, inﬂuenza
A and B, CMV, rhinovirus) and mycobacterial cultures.
c. Pneumocystis jiroveci assay (PCR, direct ﬂuorescent antibody or
cytology).
d. Viral PCR assays for CMV, HSV, VZV, HHV-6 and community
acquired respiratory virusesy.
e. Galactomannan ELISA assayy.
3. Absence of cardiac dysfunction, acute renal failure, or iatrogenic ﬂuid
overload.
CXR indicates chest x-ray; CT, computed tomography; SpO2, peripheral
capillary oxygen saturation; RSV, respiratory syncytial virus; HSV, herpes
simplex virus; VZV, varicella zoster virus; HHV-6, human herpes viruse6.
* Quantitative bacterial culture  104 colony-forming units per milliliter
considered positive.
y Per investigator discretion.
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plus radiographic evidence for diffuse alveolar injury in the
absence of infection [4]. A recent update further categorized
IPS by the primary anatomic site of cellular damage [5]. The
incidence of IPS ranges from 2% to 12%, with amedian onset 17
to 42 days after HCTandmedian time to death of 13 days from
diagnosis [1,3,5-8]. Risk factors include acute graft-versus-
host disease (GVHD) in both adult and pediatric HCT re-
cipients, with a prior history of HCT or viral pneumonitis
noted as additional risk factors in children [9-11].
Preclinical studies have revealed that inﬂammatory cyto-
kines play a role in the development of IPS [5,12-15]. Specif-
ically, TNFa contributes to endothelial cell injury and apoptosis
and directs leukocyte recruitment by regulating pulmonary
chemokine expression [12,13,15-18]. Increased levels of TNFa
and its soluble receptors have also been noted in the broncho-
alveolar lavage (BAL) ﬂuid of humans with IPS [12-15,19].
The management of IPS traditionally involves supple-
mental oxygen, systemic corticosteroids, and advanced
supportive care. Recent limited institution clinical trials us-
ing a soluble, dimeric, TNFa-binding protein (etanercept,
Enbrel; Amgen, Thousand Oaks, CA), when given in combi-
nation with systemic corticosteroids, have noted signiﬁcant
improvements in response rate and early survival for pa-
tients with IPS [3,6,20]. In collaboration with the Pediatric
Blood and Marrow Transplant Consortium and Children’s
Oncology Group, we conducted a multicenter phase II trial to
determine whether the addition of etanercept to standard
treatment would improve outcomes for children with IPS.
PATIENTS AND METHODS
Eligibility
Eligible patients were < 18 years old, received an allogeneic HCT within
the previous 120 days, and met initial clinical and radiographic criteria for
IPS. There were no exclusions to enrollment based on the underlying diag-
nosis, graft source, conditioning regimen, HLAmatch, or end-organ function.
Patients with bacteremia within the prior 48 hours, cytomegalovirus (CMV)
reactivation or CMV disease, mechanical ventilation >7 days, or a history of
tuberculosis, prior tuberculosis exposure, or chronic active hepatitis B or C
infections were ineligible. Patients receiving > 2.0 mg/kg/day methylpred-
nisolone equivalent were ineligible. Written informed consent was required
from all patients (or legal guardians). The trial was registered at Clinical-
Trials.gov as NCT00309907.
Study Design
All patients underwent BAL at study entry to establish the diagnosis of
IPS, including exclusion of infectious etiologies for the diffuse pneumonitis
(Table 1). BAL samples were collected and subsequently subdivided for as-
says, outlined in Table 1. A clinical assessment of pulmonary dysfunctionwas
obtained at study entry, recording the method of delivery and amount of
supplemental oxygen. Other required observations at study entry included
an echocardiogram (to exclude cardiogenic shock and pulmonary hyper-
tension), chest x-ray (or computed tomography scan), CMV PCR assay
(whole blood or plasma), and blood cultures. C-reactive protein (CRP),
serology, and cytokine assays were performed at study enrollment and then
weekly through day 28.
Study therapy (etanercept plus corticosteroids) was begun within 24
hours of the BAL, provided that required BAL ﬂuid microbial stains (gram
stain and fungal stain) were negative. The date therapy was initiated was
deﬁned as day 0 of study. Patients received etanercept (.4 mg/kg/dose,
maximum 25 mg) twice weekly over 4 weeks (total of 8 doses). The day
0 etanercept dose was administered intravenously to expedite attainment of
maximum plasma levels. Subsequent doses were administered subcutane-
ously 72 to 96 hours apart. If, at any point after initiation of therapy, pre-
therapy BAL ﬂuid samples became positive for a pathogen, etanercept was
discontinued and not reinstituted. The patient was considered nonevaluable
for response and replaced on the study, though he or she was still followed
for toxicity and survival.
Corticosteroids were begun at 2 mg/kg/day (methylprednisolone
equivalent) on day 0. Intravenous corticosteroids were required the ﬁrst 3
days, with subsequent change to oral dosing permitted thereafter. No dose
reduction was allowed through day 7, with subsequent taper as clinicallyindicated. Patients already receiving corticosteroids before the study had
dosing adjusted to 2 mg/kg/day on day 0. Other immunosuppressive agents
were continued, without dosing adjustment, unless clinically indicated.
Antimicrobial prophylaxis was given per local institutional practice.
Patients who developed sepsis syndrome, invasive fungal infections,
disseminated viral infections, CMV reactivation (by PCR or antigenemia
assay), or persistent bacteremia (>72 hours on appropriate antimicrobial
therapy) while undergoing study therapy were removed from the study and
not replaced. In each scenario, patients were followed for response, toxicity,
and survival. Patients who had not met the response criteria before the time
of study removal were deemed nonresponders.
Plasma Biomarker Analysis
Whole blood samples for cytokine assays were collected in heparinized
tubes on day 0 and then weekly through day 28. Frozen plasma samples
were thawed and analyzed in batch using enzyme-linked immunosorbant
(ELISA) assays for inﬂammatory cytokines, including TNFa, tumor necrosis
factor receptor 1 (TNFR1), TNFR2, IL-6, IL-8, sCD14, IFNg, angiopoietin-2
(Ang-2), and lipopolysaccharide-binding protein (LPB). Plasma samples
were also obtained from healthy controls (n ¼ 4) and allogeneic HCT re-
cipients without complications (n¼ 5). For each assay, samples were diluted
and analyzed in replicate per manufacturer’s guidelines. Plasma samples
from the transplantation controls were obtained from a separate institu-
tional review boardeapproved study.
Statistical Analysis
The primary study endpoint was response to therapy, deﬁned as survival
to day 28 of study plus complete discontinuation of supplemental oxygen
support for > 72 consecutive hours. The time to responsewas deﬁned as the
ﬁrst of 3 consecutive days off all supplemental oxygen. Secondary endpoints
included day-56 survival, overall survival (OS), and toxicity assessment us-
ing Common Terminology Criteria for Adverse Events version 3.0 (through
June 30, 2011), then Common Terminology Criteria for Adverse Events
version 4.0 thereafter. Patients were evaluable for response if they received
at least 1 dose of etanercept and their pretherapy BAL studies remained
negative for pathogen identiﬁcation. OS was computed using the Kaplan-
Meier method, with survival deﬁned from the time of study entry to the
date of death or last contact. Statistical comparisons of plasma protein levels
were performed using the nonparametric Mann-Whitney test. The study
was designed to have 90% power and type I error rate of 5% for detecting a
25% difference in response rates from 30% (historical controls) to 55%. The
planned sample size was 40 patients evaluable for response. The protocol
was approved by the Children’s Oncology Group, Pediatric Blood and
Marrow Transplant Consortium, and institutional review boards. A data
safety monitoring board, appointed by the Children’s Oncology Group,
reviewed toxicity and response assessments.
RESULTS
Thirty-nine patients enrolled between 2006 and 2011
from 22 centers, with 28 patients evaluable for response
assessment (Table 2). Eleven patients enrolled and began
Table 2
Demographics
Characteristic No. of Patients (%)
Total enrolled 39
Total eligible 28
Age, yr
Median (range) 14 (1-17)
Mean 11
Gender
Female 14 (50)
Male 14 (50)
Primary disease
ALL 10 (36)
AML/MDS 10 (36)
Lymphoma 1 (3)
Nonmalignant* 7 (25)
Stem cell source
Peripheral stem cells 3 (11)
Bone marrow 14 (50)
Cord blood 11 (39)
Conditioning regimen
TBI containingy 14 (50)
NoneTBI-containing 14 (50)
Myeloablative 27 (96)
Nonmyeloablative 1 (4)
Donor
Unrelated 24 (86)
Related 4 (14)
GVHD prophylaxis
Calcineurin inhibitorz 22 (79)
Serotherapyx 15 (54)
No serotherapy 13 (46)
Oxygen support (% FiO2 at entry)
Median FiO2 (range) 45 (25-100)
Mean FiO2 47
Oxygen support (method)k
Nasal cannula 6 (21)
Face mask/Bipap{ 5 (18)
Mechanical ventilation 17 (61)
ALL indicates acute lymphoblastic leukemia; AML, acute myeloid leukemia;
MDS, myelodysplastic syndrome; TBI, total body irradiation.
* Nonmalignant diagnosis: aplastic anemia (1), hemoglobinopathy (2),
immune-deﬁciency (4).
y TBI, total body irradiation (1200-1320 cGy).
z Tacrolimus or cyclosporine.
x Serotherapy, includes anti-thymocyte globulin or anti-CD52 mono-
clonal antibody.
k Method of supplemental oxygen support at study entry.
{ Bipap, biphasic positive airway pressure.
Figure 1. Overall survival (solid line) and 95% conﬁdence intervals (dashed
line) as a function of time since initiation of study therapy. Kaplan-Meier plot.
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because of identiﬁcation of pathogens in their pretherapy
BAL (n ¼ 10) or because of corticosteroid dosing that
exceeded study requirements (n ¼ 1).
For the 28 evaluable patients, the median time to onset of
study therapy was 20 days (range, 6 to 119) after HCT. The
median duration of pretherapy supplemental oxygen sup-
port was 2 days (range, 1 to 20 days), with the median
fraction of inspired oxygen (FiO2) of 45% (range, 25% to
100%). Seventeen of 28 patients required mechanical venti-
lator support at day 0. Twenty-three (82%) patients received
all 8 etanercept doses. Five patients failed to complete eta-
nercept dosing because of infectious (n ¼ 2) or noninfectious
(n ¼ 1) complications or death (n ¼ 2).Response and Survival
Early study closure was recommended by the data safety
monitoring board, as the primary endpoint was achieved in
20 of 28 (71%) patients. One additional complete response
occurred after day 28, bringing the overall response rate by
day 56 to 75%. The median time to complete response was 10days (range, 1 to 24 days) requiring a median of 3 doses
(range, 1 to 5) of etanercept. There were no differences in
response by gender, recipient age, underlying diagnosis, graft
source, HLAmatch, use of serotherapy for GVHD prophylaxis,
or conditioning regimen (total body irradiation versus none
total body irradiation) (data not shown). Of note, 2 of the 8
nonresponders had a clear improvement in pulmonary sta-
tus with study therapy, with both patients transitioned from
mechanical ventilation to a nasal cannula during the course
of study.
Patients requiring  45% FiO2 at study entry had higher
response rates compared with patients requiring >45% FiO2
(87% versus 54%, P ¼ .05). Complete responses were seen in
all 11 (100%) patients not requiring mechanical ventilation at
study entry, compared with responses in 9 of 17 (53%) pa-
tients on ventilatory support (P ¼ .01). A trend toward
improved response was seen in patients who initiated study
therapy within 3 days of supplemental oxygen support (83%
versus 50%, P ¼ .09). Compared with expected rates, OS was
high, 89% (95% conﬁdence interval [CI], 70% to 96%) at day 28,
75% (95% CI, 55% to 87%) at day 56, and 63% (95% CI, 42% to
79%) at 1 year (Figure 1). Fourteen patients remain alive, 305
to 1761 days after initiation of study therapy. Eight of 17
patients (47%) requiring mechanical ventilation at study
entry died within the initial 56 days of study. All 11 patients
(100%) not requiring mechanical ventilation at study entry
survived through day 56.Toxicity
Grades 3 to 5 organ toxicities occurred in 8 of 28 patients
between days 0 and 56. None of these toxicities (renal
[n ¼ 2], neurologic [n ¼ 2], gastrointestinal [n ¼ 2], cardiac
[n ¼ 1], and hepatic [n ¼ 1]) were attributed to etanercept.
Grades 3 to 5 infections occurred in 7 patients, including
CMV (n¼ 2), herpes simplex virus (n¼ 2), virus-not speciﬁed
(n¼ 1), aspergillus (n¼ 1), and bacterial enterocolitis (n¼ 1).
CMV viremia developed in 2 patients on days 19 and 40
study, respectively, 1 associated with CMV pneumonitis. Five
of the 7 grade 3 to 5 infections were pulmonary. No episodes
of septicemia were observed during the study or the obser-
vation period (days 0 to 56). Eight deaths occurred by day 56
and were secondary to progression of IPS (n ¼ 3), infectious
pneumonitis (n ¼ 3), multiorgan failure (n ¼ 1), and cardiac
arrhythmia (n ¼ 1); all 8 events occurring in the cohort of
patients requiring mechanical ventilation at study entry.
Four patients exhibited grade 2 to 4 acute GVHD at study
entry; grade 2 (n ¼ 2) and grade 3 (n ¼ 2). Two of the 4
Figure 2. Plasma biomarkers in IPS. Plasma protein levels were analyzed from patient samples collected at the time of IPS diagnosis (IPS Dx), day 7 (D7), and day 28
(D28) of study. Two control groups were included, (1) healthy, nontransplantation patients, control (NL), and (2) allogeneic transplant recipients without compli-
cations, control (BMT). Plasma samples from control (BMT) were analyzed at day 0 and day 14 after transplantation, the day-14 time point chosen to approximate the
time of onset of IPS. Data are expressed as mean  SEM. Signiﬁcant differences between groups are shown as *P < .05, **P < .01, ***P < .001.
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therapy and 2 had no change in GVHD grading. One patient
developed grade 2 GVHD while on study. The incidence and
severity of chronic GVHD were not monitored.Plasma Cytokine Analysis
Plasma samples were available for biomarker analysis in
26 of 28 patients. Mean levels of TNFR1, a surrogate marker
for TNFa, were signiﬁcantly higher in patients at study entry,
when compared with non-HCT and HCT controls (Figure 2).
The diagnosis of IPS was also associated with signiﬁcantly
higher plasma levels of IL-6, IL-8, Ang-2, LPB, and sTNFR2.
Subsequent therapy for IPS led to reductions in day-7 and
day-28 plasma levels of sTNFR1, IL-6, IL-8, Ang-2, and LPB. By
contrast, plasma levels of sTNFR2 increased during study
therapy, indicating uptake of etanercept, a TNFR2 analogue.
Levels of sTNFR1, Ang-2, and IL-8 correlated well withFigure 3. Plasma biomarker levels of IPS at the time of diagnosis and on day 7 of
analyzed from patient samples collected at the time of IPS diagnosis (IPS Dx), and on
responded (Resp) or did not respond (NR) to study therapy. Control samples were obta
complications, D14 control (BMT). Data are expressed as mean  SEM. Signiﬁcant diresponse to therapy; mean plasma levels of all 3 cytokines
declined by day 7 in responders but increased in non-
responders (Figure 3). The mean CRP level on day 0 was 28.1
 12.1, with levels decreased to 1.8  .6 in responders
compared with 5.4  3.3 in nonresponders by day 7. Though
mean CRP levels were lower in responders than non-
responders at each time point (day 7, 14, 21, 28), none of the
differences were signiﬁcant.Nonevaluable Patients
Eleven patients were deemed nonevaluable for response
assessment. In 10 cases, pathogens were identiﬁed from the
pretherapy BAL ﬂuid cultures (or PCR assays) a median 2 days
(range, 1 to 10 days) after initiation of study treatment. Vi-
ruses accounted for 9 of the 10 abnormal results, with CMV
(n ¼ 5) the most common virus identiﬁed. Two patients had
already achieved a complete response to study therapy bystudy therapy, in responders and nonresponders. Plasma protein levels were
day 7 (D7) of study. Day-7 levels are then subdivided by those patients who
ined on day 14 after transplantation in allogeneic transplant recipients without
fferences between groups are shown as: *P < .05, **P < .01, ***P < .001.
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given the abnormal BAL results, both patients were deemed
nonevaluable for response assessment.
DISCUSSION
Improved therapy options for IPS are desperately needed,
given the historically poor outcomes in both children and
adults. Response rates of 18% to 30%, with day-28 survival
<50%, have been reported when patients were treated with
high-dose corticosteroids and supportive care measures
[1-3,20]. In our current study, treatment with systemic corti-
costeroids and etanercept resulted in complete response rates
of 71%, with day-28 survival of 89% and 1-year survival of 63%.
Three other pediatric studies have conﬁrmed that IPS remains
an important complication in children, with cumulative inci-
dence rates ranging from 6.7% to 11.8% after HCT [9,10,21]. In
all 3 studies, transplantation-related mortality remained un-
acceptably high (>50%) andOS, poor [9,10,21]. Keates-Baleeiro
examined 11 pediatric patients treated for IPS with systemic
corticosteroids (n ¼ 6), in which inﬂiximab (n ¼ 2) or eta-
nercept (n ¼ 3) were added for worsening pulmonary status.
Though overall response rates were high in this report, the
median survival was only 150 days [21]. Sano noted a median
survival of only 9 days from IPS onset to death (range, 0 to 183
days) in children managed with corticosteroids and support-
ive care, with 100% mortality for those patients who required
mechanical ventilation during therapy [10].
Early recognition of the disorder, before the development
of severe pulmonary dysfunction, is key in the management
of IPS in pediatric patients. Treatment responses were
optimal when children were treated at lower baseline FiO2
values (45%) or before the requirement for mechanical
ventilation. Day-56 survival was 100% in this subset of pa-
tients (n ¼ 11), underscoring the importance of initiating
therapy before the development of severe lung injury.
Although outcomes were inferior in patients requiring me-
chanical ventilation at study entry, survival was still signiﬁ-
cantly higher than observed in other pediatric published
reports [10].
Within this context, the current trial recommended that
patients began treatment within 24 hours of performing the
on-study BAL, provided that BAL ﬂuid special stains were
negative. We found no evidence that the early initiation of
etanercept therapy increased therapy-related toxicity, even
in patients later identiﬁed with pathogens on their pre-
therapy BAL. Interestingly, 2 patients with CMV pneumonitis
had a complete response to study therapy before initiation of
anti-CMV treatment. Although only 2 patients, such results
suggest that TNF inhibition may play a potential role in CMV
therapy. Elevated levels of TNFa have been reported in neo-
nates with CMV pneumonitis but have not previously re-
ported in HCT recipients [22].
A strength of our current studywas the application of strict
diagnostic criteria, with the requirement for BAL and echo-
cardiogram in all subjects. In addition, a strict response deﬁ-
nition was used, in which patient survival with “complete”
discontinuation of all supplemental oxygen by day 28 were
required. Clinical improvement rates in affected patients may
have actually been higher, as signiﬁcant reductions in sup-
plemental oxygen support were noted in 2 additional study
subjects by day 28, both subjects deemed nonresponders.
Comparison with Adult IPS Trial
The results of this trial warrant comparisonwith a parallel
IPS study recently conducted in adults by the Blood andMarrow Transplant Clinical Trials Network (BMT CTN) [8].
Both trials had uniform eligibility (excluding age), dosing
schedules for both etanercept and corticosteroids, and
response assessments. The BMT CTN trial was a randomized,
placebo-controlled trial of corticosteroids  etanercept.
There were no signiﬁcant differences in response and sur-
vival based upon treatment assignment (etanercept or pla-
cebo). Response rates were 65% for the entire cohort, similar
to the 71% response rate seen in our pediatric IPS study.
However, in marked contrast to the dramatic survival rates
noted in our pediatric IPS study, 1-year OS was extremely
poor (<25%) for adults in both arms of the BMT CTN study.
Several differences between the 2 studiesmay account for
these ﬁndings. Over 40% of patients in the BMT CTN trial
received a reduced-intensity regimen, compared with only
4% in the pediatric IPS trial. Cytokine production, including
TNFa, is diminished after reduced-intensity regimens [23].
Hence, it is possible that IPS developing in this context may
initially be more responsive to corticosteroids alone. Cyto-
kine analysis of BAL ﬂuid and plasma from patients with IPS
after reduced-intensity conditioning regimen are pending
from the BMT CTN IPS trial and will help address this issue.
Whereas adults in the BMT CTN trial received almost exclu-
sively peripheral blood stem cells as the donor source, the
vast majority of children in the pediatric IPS trial received
marrow (50%) or cord blood (39%). Steroid responsive peri-
engraftment syndrome has been reported after cord blood
transplantation, with periengraftment respiratory distress
syndrome recognized as a subset of IPS [24-26].
Interpretation of both studies is inﬂuenced by patient
numbers. The pediatric IPS trial terminated early when it
successfully met an efﬁcacy stopping rule. In contrast, a
major limitation of the BMT CTN IPS trial was its early
termination because of poor accrual, with only 34 patients
(out of a targeted 120) randomized [8]. Thus, the BMT CTN
trial was drastically underpowered to draw any deﬁnitive
conclusions. In addition, protocol adherence signiﬁcantly
affected the BMT CTN trial; 37% of patients on the etanercept
arm received  2 etanercept doses, in several cases because
of physician/patient discretion to discontinue “blinded”
therapy. By comparison, over 80% of patients in the pediatric
IPS trial received all 8 scheduled etanercept doses, regardless
of therapy response. Hence, whereas compliance was high
on the “open label,” phase II pediatric trial, compliance (and
ultimately enrollment) on the phase III adult trial was
signiﬁcantly lower. Bronchoscopy was mandated (for diag-
nostic purposes) in both the pediatric and BMT CTN IPS trials.
Critics have contended that the requirement for bronchos-
copy may have also excluded the worst IPS cases from
enrollment in the current trials, because of physician reluc-
tance to perform a BAL in ventilated patients. The results
from the pediatric IPS trial are thus even more impressive, as
17 of 28 (61%) patients required mechanical ventilation at
study entry. The ability to ever perform the deﬁnitive phase
III trial of etanercept in children with IPS is highly unlikely.
Biomarker Studies
A key ﬁnding in our pediatric study was the association of
plasma biomarkers with response, providing further evi-
dence that inﬂammatory cytokines contribute to the patho-
genesis of IPS. Consistent with our previous work in animal
models and humans [6], elevations in proinﬂammatory cy-
tokines, including TNFRI, TNFRII, IL-6, IL-8, and LPB, a
component of the LPS cascade, were present on day 0.
Increased levels of Ang-2 have not been previously reported
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peptide ligands for the receptor tyrosine kinase, Tie-2, that is
expressed on the surface of endothelial cells (ECs) and are
known to regulate vascular integrity [27]. Ang-2 sensitizes
ECs to TNFa and regulates TNFa-induced adhesion molecule
expression, ﬁndings that directly support pre-clinical data
generated using murine IPS models [28]. Plasma levels of
Ang-2 are increased in patients with acute respiratory
distress syndrome and steroid refractory GVHD [29-32]. We
found that Ang-2 levels in the plasma of patients with IPS
were signiﬁcantly elevated compared with controls. Impor-
tantly, levels of Ang-2 returned to baseline in IPS patients
who responded to therapy, but they continued to rise in
patients who progressed.
Although results of this pediatric phase II trial are
encouraging, not all patients with IPS respond to anti-TNFa
therapy. The reasons for this remain undetermined and limit
the optimization of care. We recently analyzed the plasma
proteome of patients with IPS and identiﬁed distinct simi-
larities between IPS in humans and animal models, identi-
fying a set of IPS-associated proteins that could predict at
time of HCT which subjects would progress to IPS and
respond to etanercept therapy [33]. Hence, patients who are
“hot-wired” to respond to immunologic stress with high
levels of TNFa secretion may be more likely to respond to
medications like etanercept, whereas others may require
alternative, novel strategies. For example, prior studies by
our group suggest that other proinﬂammatory cytokines and
chemokines, including IL-6 and MCP-1, are also markedly
elevated at the onset of IPS [3,6]. Therapeutic agents tar-
geting MCP-1 and the IL-6 receptor are now available for
clinical use and could be considered as single agents or in
combination with etanercept and corticosteroids.
In addition, an effort to categorize patients with IPS based
upon the presumed anatomic site of primary injury in
conjunction with mechanistic insights gained in the labora-
tory may lead to the use of other promising, noncross reac-
tive therapeutic or preventive agents [5]. For example, it is
conceivable that approaches to maintain EC integrity may be
effective at preventing or treating IPS. The administration of
molecules that function as survival factors for ECs has been
successful in preventing endothelial damage and mortality
from septic shock and radiation injury. Similarly, ongoing
studies examining the role of surfactant replacement therapy
might prove useful in overcoming the effects of epithelial
injury and dysfunction. Finally, as IPS develops and pro-
gresses to respiratory failure despite conventional immune
suppression, it is possible that novel strategies directed to-
ward inhibiting pathways of leukocyte recruitment to the
lung may serve as future adjuncts to standard therapy. Such
strategies have been successful in early phase studies for
GVHD prevention [34].
Etanercept Administration
Questions remain regarding the optimal route and
administration schedule for etanercept in the management
of IPS. The current trial used a 4-week course of therapy, with
a median time to response of 10 days (3 doses of etanercept).
Based upon results from the current trial, a shorter course of
therapy, which could reduce the risks of opportunistic in-
fections, may bewarranted. Although “recurrent IPS”was not
an issue in responders, whether this was because TNFa
neutralization was continued for 4 weeks remains to be
determined. Ideally, therapy would be guided by “real-time”
monitoring of cytokine levels, with such technologycurrently under development at centers. In addition, the
current study mandated that the ﬁrst etanercept dose be
given intravenously, with subsequent dosing via subcu-
taneous administration. Intravenous dosing was safe in our
study, and not associated with infusion related events. Prior
pharmaco-kinetic data noted a rapid attainment of maximal
concentration (Cmax) after intravenous administration of
etanercept, in comparison to subcutaneous dosing [35].
Given the critical nature of affected patients, the importance
of rapid attainment of Cmax is evident, and intravenous
etanercept dosing remains recommended at initiation of IPS
therapy.
In conclusion, etanercept in combination with cortico-
steroids was associated with high response rates and OS in
children with IPS. Therapy was well tolerated with an
acceptable toxicity proﬁle. Plasma biomarker studies further
support the role for inﬂammatory cytokines in the patho-
genesis of IPS, with reductions in biomarker levels coinciding
with clinical response to therapy. Collectively, these results
represent the culmination of a translational research
endeavor that used established animal models, encouraging
early phase clinical data and 2 collaborative pediatric con-
sortium to bring novel insights into the pathophysiology of a
lethal clinical disorder, from the laboratory to the clinic.ACKNOWLEDGMENTS
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